GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Geovax Labs Inc (NAS:GOVX) » Definitions » Shiller PE Ratio

Geovax Labs (Geovax Labs) Shiller PE Ratio : (As of May. 14, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Geovax Labs Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Geovax Labs Shiller PE Ratio Historical Data

The historical data trend for Geovax Labs's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Geovax Labs Shiller PE Ratio Chart

Geovax Labs Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Geovax Labs Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Geovax Labs's Shiller PE Ratio

For the Biotechnology subindustry, Geovax Labs's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Geovax Labs's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Geovax Labs's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Geovax Labs's Shiller PE Ratio falls into.



Geovax Labs Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Geovax Labs's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Geovax Labs's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-3.94/129.4194*129.4194
=-3.940

Current CPI (Dec. 2023) = 129.4194.

Geovax Labs Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 -13.367 99.695 -17.353
201406 -14.748 100.560 -18.981
201409 -11.166 100.428 -14.389
201412 -20.044 99.070 -26.184
201503 -15.202 99.621 -19.749
201506 -14.676 100.684 -18.865
201509 -13.454 100.392 -17.344
201512 -15.034 99.792 -19.497
201603 -28.133 100.470 -36.239
201606 -12.497 101.688 -15.905
201609 -10.074 101.861 -12.800
201612 -20.301 101.863 -25.793
201703 -3,000,000.000 102.862 -3,774,546.918
201706 -11.218 103.349 -14.048
201709 -12.778 104.136 -15.880
201712 -11.203 104.011 -13.940
201803 -13.495 105.290 -16.588
201806 -13.826 106.317 -16.830
201809 -14.473 106.507 -17.587
201812 -13.767 105.998 -16.809
201903 -701,454.000 107.251 -846,445.991
201906 -654,148.000 108.070 -783,379.600
201909 -2,669.400 108.329 -3,189.089
201912 -591.184 108.420 -705.687
202003 -38.100 108.902 -45.278
202006 -9.900 108.767 -11.780
202009 -10.950 109.815 -12.905
202012 -5.230 109.897 -6.159
202103 -4.350 111.754 -5.038
202106 -3.150 114.631 -3.556
202109 -4.650 115.734 -5.200
202112 -33.600 117.630 -36.968
202203 -5.100 121.301 -5.441
202206 -2.700 125.017 -2.795
202209 -2.550 125.227 -2.635
202212 -3.067 125.222 -3.170
202303 -2.250 127.348 -2.287
202306 -3.300 128.729 -3.318
202309 -4.800 129.860 -4.784
202312 -3.940 129.419 -3.940

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Geovax Labs  (NAS:GOVX) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Geovax Labs Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Geovax Labs's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Geovax Labs (Geovax Labs) Business Description

Traded in Other Exchanges
Address
1900 Lake Park Drive, Suite 380, Smyrna, GA, USA, 30080
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors.
Executives
Mckee Kelly T. Jr. officer: Chief Medical Officer 233 VALLEY MEADOW DRIVE, CHAPEL HILL NC 27516
David A Dodd director C/O SEROLOGICALS CORP, 5565 SPALDING DR, NORCROSS GA 30092
Mark Reynolds officer: Chief Financial Officer TWO BALA PLAZA, SUITE 300, PHILADELPHIA PA 19004
Jayne Morgan director 1900 LAKE PARK DRIVE, SUITE 380, SMYRNA GA 30080
Randal D Chase director 28 GEORGIA COURT, RICHMOND HILL A6 L4E ON7
Nicole Lemerond director 3 MURRAY HILL ROAD, SCARSDALE NY 10583
John W. Sharkey officer: VP, Business Development 16857 E. SAGUARO BLVD., FOUNTAIN HILLS AZ 85268
Dean G Kollintzas director 1256 BRIARCLIFF ROAD N.E., EMTECH BIO SUITE 500, ATLANTA GA 30306
Spencer John N Jr director 2859 PACES FERRY RD, STE 1000, ATLANTA GA 30339
Robert T Mcnally director
Farshad Guirakhoo officer: Sr VP, Research & Development 39 CHESTNUT STREET, MELROSE MA 02176
Steven S. Antebi director 10550 FONTENELLE WAY, LOS ANGELES CA 90077
Harriet L Robinson other: Chair, Scientific Adv Brd 1256 BRIARCLIFF ROAD N.E., EMTECH BIO SUITE 500, ATLANTA GA 30306
Mark J Newman officer: VP, Research & Development 1900 LAKE PARK DR, SUITE 380, SMYRNA GA 30080
Peter M Tsolinas director 123 JOAN DRIVE, BARRINGTON IL 60010